Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.

Conclusions: The case expands the understanding of secondary CML and emphasizes the importance of oncological vigilance in patients with secondary CML after AML therapy. PMID: 32936052 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research

Related Links:

Corcos Eric Lippert Since the discovery of spliceosome mutations in myeloid malignancies, abnormal pre-mRNA splicing, which has been well studied in various cancers, has attracted novel interest in hematology. However, despite the common occurrence of spliceosome mutations in myelo-proliferative neoplasms (MPN), not much is known regarding the characterization and mechanisms of splicing anomalies in MPN. In this article, we review the current scientific literature regarding “splicing and myeloproliferative neoplasms”. We first analyse the clinical series reporting spliceosome mutations in MPN and ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
T cell cancer neoantigens are created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface. Because expression of the aberrant target protein is exclusive to malignant cells, immunotherapy directed against neoantigens should avoid “on-target, off-tumor” toxicity. The efficacy of neoantigen vaccines in melanoma and glioblastoma and of adoptive transfer of neoantigen-specific T cells in epithelial tumors indicates that neoantigens are valid therapeutic targets. Improvements in sequencing tec...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Publication date: Available online 7 February 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Stephan Bartels, Britta Hasemeier, Julia Vogtmann, Elisa Schipper, Guntram Büsche, Jerome Schlue, Hans Kreipe, Ulrich LehmannAbstractChromosomal translocations resulting in fusion genes represent important oncogenic drivers and potential therapeutic targets in rare leukemia subtypes. Formalin-fixed and paraffin-embedded trephines are frequently used in hematologic diagnostic and provide relevant access to leukemic cells for further studies, e.g. phenotyping in bone marrow fibrosis. However, high-throughput molecula...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
We present a retrospective analysis of several reduced intensity conditioning (RIC) regimens. Methods This was a retrospective study with an aim of comparing survival outcomes in patients with myeloid disorders [acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic disorders (MDS), and myeloproliferative neoplasms (MPN)] who underwent HCT at our institution between the years 2008-2017.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 235 Source Type: research
Conclusions The discovery of JAK2V617F mutation in BCR-ABL1-negative MPNs by four different international cooperative groups in 2005 (2–5) led to significant insights on the pathogenesis of these disorders. In fact, this mutation results in a gain-of-function with activation of cytokine and growth factor receptors, and thus of the downstream JAK-STAT pathway (79, 95–98). The JAK2 point mutation in exon 12, present in a small percentage of patients with PV, is able to induce the MPN phenotype through the same pathogenic mechanism (6, 7). In 2006 the MPLW515L/K was reported in ET and PMF patients (44, 45) and d...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Acute Myeloid Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Dysplasia;   Essential Thrombocythemia;   FGFR1 Gene Rearrangement;   M yelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid Neoplasm;   Myeloproliferativ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 19 December 2018Source: The Journal of Molecular DiagnosticsAuthor(s): Guilin Tang, Shimin Hu, Sa A. Wang, Wei Xie, Pei Lin, Jie Xu, Gokce Toruner, Ming Zhao, Jun Gu, Madison Doty, Shaoying Li, L. Jeffrey Medeiros, Zhenya Tangt(3;8)(q26.2;q24) is a rare recurrent cytogenetic abnormality that is associated with myeloid neoplasms. Of 20 patients with t(3;8)(q26.2,q24), 8 had therapy-related acute myeloid leukemia (AML), 3 therapy-related myelodysplastic syndrome, 4 blast phase of chronic myeloid leukemia, 1 relapsed AML, 1 AML transformed from chronic myelomonocytic leukemia, 1 blast phase ...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
We report 20 patients with t(3;8)(q26.2,q24): eight had therapy-related acute myeloid leukemia (AML), three therapy-related myelodysplastic syndrome, four blast phase of chronic myeloid leukemia, one relapsed AML, one AML transformed from chronic myelomonocytic leukemia, one blast phase of an unclassifiable myeloproliferative neoplasm, one de novo myelodysplastic syndrome, and one de novo AML. Nineteen patients presented with cytopenia. Multilineage dysplasia was observed in 16/18 patients, and megakaryocytes were markedly decreased in 11/20 patients. Blasts showed a primitive myeloid immunophenotype in 17 patients, negati...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
t(3;8)(q26.2;q24) is a rare recurrent cytogenetic abnormality that is associated with myeloid neoplasms. Of 20 patients with t(3;8)(q26.2,q24), 8 had therapy-related acute myeloid leukemia (AML), 3 therapy-related myelodysplastic syndrome, 4 blast phase of chronic myeloid leukemia, 1 relapsed AML, 1 AML transformed from chronic myelomonocytic leukemia, 1 blast phase of an unclassifiable myeloproliferative neoplasm, 1 de novo myelodysplastic syndrome, and 1 de novo AML. Nineteen patients presented with cytopenia.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Regular article Source Type: research
ConclusionOur first-in-human clinical trial demonstrates promising efficacy of cCAR therapy in treating patients with relapsed/ refractory AML. cCAR is able to eradicate leukemia blasts and leukemia stem cells, exerting a profound tumor killing effect that is superior to single target CAR T cell therapies. cCAR is also shown to induce total myeloid ablation in bone marrow, suggesting that it may act as a safer alternative to avoid the severe toxicities caused by standard bone marrow ablation regimens without sacrificing the anti-tumor efficacy. This strategy will likely benefit patients who are unable to tolerate total bod...
Source: Blood - Category: Hematology Authors: Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Immunotherapy Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Chronic Leukemia | Chronic Myeloid Leukaemia | Dexamethasone | Leukemia | Methotrexate | Middle East Health | Myeloproliferative Disorders | Research | Stem Cell Therapy | Stem Cells | Transplants